Literature DB >> 8358987

Increased levels of urinary collagen crosslinks in females with rheumatoid arthritis.

T D Spector1, I T James, G M Hall, P W Thompson, D Perrett, D J Hart.   

Abstract

Bone loss is a feature of RA, but the exact mechanisms involved are not clear. The collagen crosslinks deoxypyridinoline (DPYR) and pyridinoline (PYR) are specific indices of 'mature' collagen breakdown and reflect increased bone turnover. The aims of the study were to examine crosslink levels in RA and their association with disease activity and the effect of steroids. Urinary crosslinks corrected for creatinine were measured on morning fasting samples by HPLC in 70 postmenopausal women with rheumatoid arthritis (RA) aged 45-65 and compared with 169 postmenopausal healthy age-matched controls from the population. Mean levels of PYR were significantly higher in RA cases than in controls (52.4 versus 37.5 nmols/mmolCr) although mean levels of DPYR did not differ significantly. A weak correlation was found with ESR and PYR (r = 0.35) but not with other markers of disease activity. Thirteen of the RA cases were current steroid users and their levels of DPYR and PYR even with low doses, were significantly elevated above those of non-users, ex-users and controls. The finding of raised urinary PYR but not the bone specific DPYR in nonsteroid using RA cases suggests that the increased collagen breakdown does not primarily come from bone but from other sources such as cartilage and synovium. The large increases in collagen excretion in low dose steroid users, may reflect the higher risk of osteoporosis in this group.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8358987     DOI: 10.1007/BF02231535

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  13 in total

1.  Markers of bone turnover in rheumatoid arthritis.

Authors:  J D Adachi
Journal:  J Rheumatol       Date:  1991-08       Impact factor: 4.666

2.  Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography.

Authors:  D Black; A Duncan; S P Robins
Journal:  Anal Biochem       Date:  1988-02-15       Impact factor: 3.365

3.  Bone GLA protein (BGP) levels and bone turnover in rheumatoid arthritis.

Authors:  M Magaro; L Altomonte; L Mirone; A Zoli; G Corvino
Journal:  Br J Rheumatol       Date:  1989-06

4.  Radiochemical determination of the metabolic activity of collagen in mature dentin.

Authors:  J M Borggreven; P M Hoppenbrouwers; R Gorissen
Journal:  J Dent Res       Date:  1979-11       Impact factor: 6.116

5.  Rapid assay for hard tissue collagen cross-links using isocratic ion-pair reversed-phase liquid chromatography.

Authors:  I T James; D Perrett; P W Thompson
Journal:  J Chromatogr       Date:  1990-01-26

6.  Analysis of pyridinoline, a cross-linking compound of collagen fibers, in human urine.

Authors:  D Fujimoto; M Suzuki; A Uchiyama; S Miyamoto; T Inoue
Journal:  J Biochem       Date:  1983-10       Impact factor: 3.387

7.  Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography.

Authors:  D R Eyre; T J Koob; K P Van Ness
Journal:  Anal Biochem       Date:  1984-03       Impact factor: 3.365

8.  Urinary excretion of the hydroxypyridinium cross links of collagen in patients with rheumatoid arthritis.

Authors:  D Black; M Marabani; R D Sturrock; S P Robins
Journal:  Ann Rheum Dis       Date:  1989-08       Impact factor: 19.103

9.  Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases.

Authors:  M J Seibel; A Duncan; S P Robins
Journal:  J Rheumatol       Date:  1989-07       Impact factor: 4.666

10.  Measures of bone loss in rheumatoid arthritis.

Authors:  M H Weisman; R W Orth; B D Catherwood; S C Manolagas; L J Deftos
Journal:  Arch Intern Med       Date:  1986-04
View more
  8 in total

1.  Quantitative analysis of pyridinium crosslinks of collagen in the synovial fluid of patients with rheumatoid arthritis using high-performance liquid chromatography.

Authors:  A Müller; G Hein; S Franke; D Herrmann; S Henzgen; A Roth; G Stein
Journal:  Rheumatol Int       Date:  1996       Impact factor: 2.631

2.  The determination of pyridinium crosslinks in urine and serum as a possible marker of cartilage degradation in rheumatoid arthritis.

Authors:  G Hein; S Franke; A Müller; E Bräunig; T Eidner; G Stein
Journal:  Clin Rheumatol       Date:  1997-03       Impact factor: 2.980

3.  Vitamin D receptor gene polymorphism in rheumatoid arthritis and associated osteoporosis.

Authors:  Péter Rass; Angéla Pákozdi; Péter Lakatos; Erika Zilahi; Sándor Sipka; Gyula Szegedi; Zoltán Szekanecz
Journal:  Rheumatol Int       Date:  2006-01-31       Impact factor: 2.631

4.  Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis.

Authors:  W F Lems; M I Gerrits; J W Jacobs; R M van Vugt; H J van Rijn; J W Bijlsma
Journal:  Ann Rheum Dis       Date:  1996-05       Impact factor: 19.103

5.  Concentrations of pyridinoline and deoxypyridinoline in joint tissues from patients with osteoarthritis or rheumatoid arthritis.

Authors:  M Takahashi; K Kushida; H Hoshino; M Suzuki; M Sano; S Miyamoto; T Inoue
Journal:  Ann Rheum Dis       Date:  1996-05       Impact factor: 19.103

6.  Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis.

Authors:  L Sinigaglia; M Varenna; L Binelli; F Bartucci; M Arrigoni; R Ferrara; G Abbiati
Journal:  Ann Rheum Dis       Date:  1995-02       Impact factor: 19.103

7.  Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis.

Authors:  Kageyama Yasunori; Takahashi Masaaki; Nagafusa Tetsuyuki; Kobayashi Hayato; Nagano Akira
Journal:  Clin Rheumatol       Date:  2008-03-13       Impact factor: 2.980

8.  The urinary excretion of pyridinoline and deoxypyridinoline during rheumatoid arthritis therapy with infliximab.

Authors:  Lidia Ostanek; Andrzej Pawlik; Iwona Brzosko; Marek Brzosko; Rozalia Sterna; Marek Droździk; Barbara Gawrońska-Szklarz
Journal:  Clin Rheumatol       Date:  2004-02-26       Impact factor: 2.980

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.